PD-1 expression on tumor-specific T cells: Friend or foe for immunotherapy?

References

• Ishida Y, Agata Y, Shibahara K, Honjo T. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J 1992;11:3887-95. PMID:1396582
   PubMed Web of Science ®Google Scholar
• Nishimura H, Nose M, Hiai H, Minato N, Honjo T. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 1999;11:141-51. doi:10.1016/S1074-7613(00)80089-8. PMID:10485649
   PubMed Web of Science ®Google Scholar
• Petrovas C, Casazza JP, Brenchley JM, Price DA, Gostick E, Adams WC, Precopio ML, Schacker T, Roederer M, Douek DC, et al. PD-1 is a regulator of virus-specific CD8+ T cell survival in HIV infection. J Exp Med. 2006;203:2281-92. doi:10.1084/jem.20061496. PMID:16954372
   PubMed Web of Science ®Google Scholar
• Liu Y, Yu Y, Yang S, Zeng B, Zhang Z, Jiao G, Zhang Y, Cai L, Yang R. Regulation of arginase I activity and expression by both PD-1 and CTLA-4 on the myeloid-derived suppressor cells. Cancer Immunol Immunother. 2009;58:687-97. doi:10.1007/s00262-008-0591-5. PMID:18828017
   PubMed Web of Science ®Google Scholar
• Chikuma S, Terawaki S, Hayashi T, Nabeshima R, Yoshida T, Shibayama S, Okazaki T, Honjo T. PD-1-mediated suppression of IL-2 production induces CD8+ T cell anergy in vivo. J Immunol. 2009;182:6682-9. doi:10.4049/jimmunol.0900080. PMID:19454662
   PubMed Web of Science ®Google Scholar
• Youngblood B, Oestreich KJ, Ha S-J, Duraiswamy J, Akondy RS, West EE, Wei Z, Lu P, Austin JW, Riley JL, et al. Chronic virus infection enforces demethylation of the locus that encodes PD-1 in antigen-specific CD8(+) T cells. Immunity. 2011;35:400-12. doi:10.1016/j.immuni.2011.06.015. PMID:21943489
   PubMed Web of Science ®Google Scholar
• Yokosuka T, Takamatsu M, Kobayashi-Imanishi W, Hashimoto-Tane A, Azuma M, Saito T. Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2. J Exp Med. 2012;209:1201-17. doi:10.1084/jem.20112741. PMID:22641383
   PubMed Web of Science ®Google Scholar
• Hui E, Cheung J, Zhu J, Su X, Taylor MJ, Wallweber HA, Sasmal DK, Huang J, Kim JM, Mellman I, et al. T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition. Science. 2017;355:1428-33. doi:10.1126/science.aaf1292. PMID:28280247
   PubMed Web of Science ®Google Scholar
• Ahmadzadeh M, Johnson LA, Heemskerk B, Wunderlich JR, Dudley ME, White DE, Rosenberg SA. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood. 2009;114:1537-44. doi:10.1182/blood-2008-12-195792. PMID:19423728
   PubMed Web of Science ®Google Scholar
• Fourcade J, Kudela P, Sun Z, Shen H, Land SR, Lenzner D, Guillaume P, Luescher IF, Sander C, Ferrone S, et al. PD-1 is a regulator of NY-ESO-1-specific CD8+ T cell expansion in melanoma patients. J Immunol. 2009;182:5240-9. doi:10.4049/jimmunol.0803245. PMID:19380770
   PubMed Web of Science ®Google Scholar
• Fourcade J, Sun Z, Benallaoua M, Guillaume P, Luescher IF, Sander C, Kirkwood JM, Kuchroo V, Zarour HM. Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients. J Exp Med. 2010;207:2175-86. doi:10.1084/jem.20100637. PMID:20819923
   PubMed Web of Science ®Google Scholar
• Chauvin JM, Pagliano O, Fourcade J, Sun Z, Wang H, Sander C, Kirkwood JM, Chen TH, Maurer M, Korman AJ, et al. TIGIT and PD-1 impair tumor antigen-specific CD8(+) T cells in melanoma patients. J Clin Invest. 2015;125:2046-58. doi:10.1172/JCI80445. PMID:25866972
   PubMed Web of Science ®Google Scholar
• Inozume T, Hanada K-I, Wang QJ, Ahmadzadeh M, Wunderlich JR, Rosenberg SA, Yang JC. Selection of CD8+PD-1+ lymphocytes in fresh human melanomas enriches for tumor-reactive T cells. J Immunother. 2010;33:956-64. doi:10.1097/CJI.0b013e3181fad2b0. PMID:20948441
   PubMed Web of Science ®Google Scholar
• Gros A, Robbins PF, Yao X, Li YF, Turcotte S, Tran E, Wunderlich JR, Mixon A, Farid S, Dudley ME, et al. PD-1 identifies the patient-specific CD8(+) tumor-reactive repertoire infiltrating human tumors. J Clin Invest. 2014;124:2246-59. doi:10.1172/JCI73639. PMID:24667641
   PubMed Web of Science ®Google Scholar
• Simon S, Vignard V, Florenceau L, Dreno B, Khammari A, Lang F, Labarriere N. PD-1 expression conditions T cell avidity within an antigen-specific repertoire. Oncoimmunology. 2016;5:e1104448. doi:10.1080/2162402X.2015.1104448. PMID:26942093.
   PubMed Web of Science ®Google Scholar
• Gros A, Parkhurst MR, Tran E, Pasetto A, Robbins PF, Ilyas S, Prickett TD, Gartner JJ, Crystal JS, Roberts IM, et al. Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients. Nat Med. 2016;22:433-8. doi:10.1038/nm.4051. PMID:26901407
   PubMed Web of Science ®Google Scholar
• Pauken KE, Wherry EJ. Overcoming T cell exhaustion in infection and cancer. Trends Immunol. 2015;36:265-76. doi:10.1016/j.it.2015.02.008. PMID:25797516.
   PubMed Web of Science ®Google Scholar
• Singer M, Wang C, Cong L, Marjanovic ND, Kowalczyk MS, Zhang H, Nyman J, Sakuishi K, Kurtulus S, Gennert D, et al. A Distinct Gene Module for Dysfunction Uncoupled from Activation in Tumor-Infiltrating T Cells. Cell. 2016;166:1500-9. doi:10.1016/j.cell.2016.08.052. PMID:27610572
   PubMed Web of Science ®Google Scholar
• Wang C, Singer M, Anderson AC. Molecular Dissection of CD8(+) T-Cell Dysfunction. Trends Immunol. 2017;. doi:10.1016/j.it.2017.05.008
   Web of Science ®Google Scholar
• Chen L, Han X. Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future. J Clin Invest. 2015;125:3384-91. doi:10.1172/JCI80011. PMID:26325035
   PubMed Web of Science ®Google Scholar
• Oestreich KJ, Yoon H, Ahmed R, Boss JM. NFATc1 regulates PD-1 expression upon T cell activation. J Immunol. 2008;181:4832-9. doi:10.4049/jimmunol.181.7.4832. PMID:18802087
   PubMed Web of Science ®Google Scholar
• Youngblood B, Noto A, Porichis F, Akondy RS, Ndhlovu ZM, Austin JW, Bordi R, Procopio FA, Miura T, Allen TM, et al. Cutting edge: Prolonged exposure to HIV reinforces a poised epigenetic program for PD-1 expression in virus-specific CD8 T cells. J Immunol. 2013;191:540-4. doi:10.4049/jimmunol.1203161. PMID:23772031
   PubMed Web of Science ®Google Scholar
• Ahn E, Youngblood B, Lee J, Lee J, Sarkar S, Ahmed R. Demethylation of the PD-1 Promoter Is Imprinted during the Effector Phase of CD8 T Cell Exhaustion. J Virol. 2016;90:8934-46. doi:10.1128/JVI.00798-16. PMID:27466420
   PubMed Web of Science ®Google Scholar
• McPherson RC, Konkel JE, Prendergast CT, Thomson JP, Ottaviano R, Leech MD, Kay O, Zandee SEJ, Sweenie CH, Wraith DC, et al. Epigenetic modification of the PD-1 (Pdcd1) promoter in effector CD4(+) T cells tolerized by peptide immunotherapy. Elife. 2014;3:765. doi:10.7554/eLife.03416
   Web of Science ®Google Scholar
• Martinez GJ, Pereira RM, Äijö T, Kim EY, Marangoni F, Pipkin ME, Togher S, Heissmeyer V, Zhang YC, Crotty S, et al. The transcription factor NFAT promotes exhaustion of activated CD8+ T cells. Immunity. 2015;42:265-78. doi:10.1016/j.immuni.2015.01.006. PMID:25680272
   PubMed Web of Science ®Google Scholar
• Chen L, Flies DB. Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol. 2013;13:227-42. doi:10.1038/nri3405. PMID:23470321
   PubMed Web of Science ®Google Scholar
• Lu P, Youngblood BA, Austin JW, Mohammed AUR, Butler R, Ahmed R, Boss JM. Blimp-1 represses CD8 T cell expression of PD-1 using a feed-forward transcriptional circuit during acute viral infection. J Exp Med. 2014;211:515-27. doi:10.1084/jem.20130208. PMID:24590765
   PubMed Web of Science ®Google Scholar
• Scott-Browne JP, López-Moyado IF, Trifari S, Wong V, Chavez L, Rao A, Pereira RM. Dynamic Changes in Chromatin Accessibility Occur in CD8(+) T Cells Responding to Viral Infection. Immunity. 2016;45:1327-40. doi:10.1016/j.immuni.2016.10.028. PMID:27939672
   PubMed Web of Science ®Google Scholar
• Pauken KE, Sammons MA, Odorizzi PM, Manne S, Godec J, Khan O, Drake AM, Chen Z, Sen DR, Kurachi M, et al. Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade. Science. 2016;354:1160-5. doi:10.1126/science.aaf2807. PMID:27789795
   PubMed Web of Science ®Google Scholar
• Sen DR, Kaminski J, Barnitz RA, Kurachi M, Gerdemann U, Yates KB, Tsao H-W, Godec J, LaFleur MW, Brown FD, et al. The epigenetic landscape of T cell exhaustion. Science. 2016;354:1165-9. doi:10.1126/science.aae0491. PMID:27789799
   PubMed Web of Science ®Google Scholar
• Staron MM, Gray SM, Marshall HD, Parish IA, Chen JH, Perry CJ, Cui G, Li MO, Kaech SM. The transcription factor FoxO1 sustains expression of the inhibitory receptor PD-1 and survival of antiviral CD8(+) T cells during chronic infection. Immunity. 2014;41:802-14. doi:10.1016/j.immuni.2014.10.013. PMID:25464856
   PubMed Web of Science ®Google Scholar
• Quigley M, Pereyra F, Nilsson B, Porichis F, Fonseca C, Eichbaum Q, Julg B, Jesneck JL, Brosnahan K, Imam S, et al. Transcriptional analysis of HIV-specific CD8+ T cells shows that PD-1 inhibits T cell function by upregulating BATF. Nat Med. 2010;16:1147-51. doi:10.1038/nm.2232. PMID:20890291
   PubMed Web of Science ®Google Scholar
• Badoual C, Hans S, Merillon N, Van Ryswick C, Ravel P, Benhamouda N, Levionnois E, Nizard M, Si-Mohamed A, Besnier N, et al. PD-1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer. Cancer Res. 2013;73:128-38. doi:10.1158/0008-5472.CAN-12-2606. PMID:23135914
   PubMed Web of Science ®Google Scholar
• Kawakami Y, Eliyahu S, Sakaguchi K, Robbins PF, Rivoltini L, Yannelli JR, Appella E, Rosenberg SA. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J Exp Med 1994;180:347-52. doi:10.1084/jem.180.1.347. PMID:7516411
   PubMed Web of Science ®Google Scholar
• Coulie PG, Brichard V, Van Pel A, Wolfel T, Schneider J, Traversari C, Mattei S, De Plaen E, Lurquin C, Szikora JP, et al. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med 1994;180:35-42. doi:10.1084/jem.180.1.35. PMID:8006593
   PubMed Web of Science ®Google Scholar
• Godet Y, Moreau-Aubry A, Guilloux Y, Vignard V, Khammari A, Dreno B, Jotereau F, Labarriere N. MELOE-1 is a new antigen overexpressed in melanomas and involved in adoptive T cell transfer efficiency. J Exp Med. 2008;205:2673-82. doi:10.1084/jem.20081356. PMID:18936238
   PubMed Web of Science ®Google Scholar
• Allard M, Couturaud B, Carretero-Iglesia L, Duong MN, Schmidt J, Monnot GC, Romero P, Speiser DE, Hebeisen M, Rufer N. TCR-ligand dissociation rate is a robust and stable biomarker of CD8+ T cell potency. JCI Insight. 2017;2. doi:10.1172/jci.insight.92570. PMID:28724801
   PubMed Web of Science ®Google Scholar
• Zahm CD, Colluru V, McNeel DG. Vaccination with High-Affinity Epitopes Impairs Antitumor Efficacy by Increasing PD-1Expression on CD8+ T Cells. Cancer Immunol Res. 2017;: canimm.0374.2016. doi:10.1158/2326-6066.CIR-16-0374. PMID:28634215
   PubMed Web of Science ®Google Scholar
• Tirosh I, Izar B, Prakadan SM, Wadsworth MH, Treacy D, Trombetta JJ, Rotem A, Rodman C, Lian C, Murphy G, et al. Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. Science. 2016;352:189-96. doi:10.1126/science.aad0501. PMID:27124452
   PubMed Web of Science ®Google Scholar
• Topalian SL, Taube JM, Anders RA, Pardoll DM. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer. 2016;16:275-87. doi:10.1038/nrc.2016.36. PMID:27079802
   PubMed Web of Science ®Google Scholar
• Tumeh, P. C, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, Chmielowski B, Spasic M, Henry G, Ciobanu V, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515:568-71. doi:10.1038/nature13954. PMID:25428505
   PubMed Web of Science ®Google Scholar
• Hamid O, Robert C, Daud A, Hodi FS, Hwu W-J, Kefford R, Wolchok JD, Hersey P, Joseph RW, Weber JS, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med. 2013;369:134-44. doi:10.1056/NEJMoa1305133. PMID:23724846
   PubMed Web of Science ®Google Scholar
• Ribas A, Shin DS, Zaretsky J, Frederiksen J, Cornish A, Avramis E, Seja E, Kivork C, Siebert J, Kaplan-Lefko P, et al. PD-1 Blockade Expands Intratumoral Memory T Cells. Cancer Immunol Res. 2016;4:194-203. doi:10.1158/2326-6066.CIR-15-0210. PMID:26787823
   PubMed Web of Science ®Google Scholar
• Ribas A, Robert C, Hodi FS, Wolchok JD, Joshua AM, Hwu W-J, Weber JS, Zarour HM, Kefford R, Loboda A, et al. Association of response to programmed death receptor 1 (PD-1) blockade with pembrolizumab (MK-3475) with an interferon-inflammatory immune gene signature. JCO. 2015;33:3001-1
   Web of Science ®Google Scholar
• Teng MWL, Ngiow SF, Ribas A, Smyth MJ. Classifying Cancers Based on T-cell Infiltration and PD-L1. Cancer Res. 2015;75:2139-45. doi:10.1158/0008-5472.CAN-15-0255. PMID:25977340
   PubMed Web of Science ®Google Scholar
• Johnson DB, Estrada MV, Salgado R, Sanchez V, Doxie DB, Opalenik SR, Vilgelm AE, Feld E, Johnson AS, Greenplate AR, et al. Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy. Nat Commun. 2016;7:10582. doi:10.1038/ncomms10582. PMID:26822383
   PubMed Web of Science ®Google Scholar
• Kamphorst AO, Pillai RN, Yang S, Nasti TH, Akondy RS, Wieland A, Sica GL, Yu K, Koenig L, Patel NT, et al. Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1-targeted therapy in lung cancer patients. Proc Natl Acad Sci USA. 2017;114:4993-8. doi:10.1073/pnas.1705327114. PMID:28446615.
   PubMed Web of Science ®Google Scholar
• Labarriere N, Fortun A, Bellec A, Khammari A, Dreno B, Saiagh S, Lang F. A full GMP process to select and amplify epitope-specific T lymphocytes for adoptive immunotherapy of metastatic melanoma. Clin Dev Immunol. 2013;2013:932318. doi:10.1155/2013/932318. PMID:24194775
   PubMed Web of Science ®Google Scholar
• Fernandez-Poma SM, Salas-Benito D, Lozano T, Casares N, Riezu-Boj J-I, Mancheño U, Elizalde E, Alignani D, Zubeldia N, Otano I, et al. Expansion of Tumor-Infiltrating CD8(+) T cells Expressing PD-1 Improves the Efficacy of Adoptive T-cell Therapy. Cancer Res. 2017;77:3672-84. doi:10.1158/0008-5472.CAN-17-0236. PMID:28522749
   PubMed Web of Science ®Google Scholar
• Jing W, Gershan JA, Blitzer GC, Palen K, Weber J, McOlash L, Riese M, Johnson BD. Adoptive cell therapy using PD-1(+) myeloma-reactive T cells eliminates established myeloma in mice. J Immunother Cancer. 2017;5:51. doi:10.1186/s40425-017-0256-z. PMID:28642819
   PubMed Web of Science ®Google Scholar
• Lloyd A, Vickery ON, Laugel B. Beyond the antigen receptor: editing the genome of T-cells for cancer adoptive cellular therapies. Front Immunol. 2013;4:221. doi:10.3389/fimmu.2013.00221. PMID:23935598
   PubMed Web of Science ®Google Scholar
• Wang W, Ye C, Liu J, Zhang D, Kimata JT, Zhou P. CCR5 gene disruption via lentiviral vectors expressing Cas9 and single guided RNA renders cells resistant to HIV-1 infection. PLoS ONE. 2014;9:e115987. doi:10.1371/journal.pone.0115987. PMID:25541967
   PubMed Web of Science ®Google Scholar
• Su S, Hu B, Shao J, Shen B, Du J, Du Y, Zhou J, Yu L, Zhang L, Chen F, et al. CRISPR-Cas9 mediated efficient PD-1 disruption on human primary T cells from cancer patients. Sci Rep. 2016;6:20070. doi:10.1038/srep20070. PMID:26818188
   PubMed Web of Science ®Google Scholar
• Menger L, Sledzinska A, Bergerhoff K, Vargas FA, Smith J, Poirot L, Pule M, Hererro J, Peggs KS, Quezada SA. TALEN-Mediated Inactivation of PD-1 in Tumor-Reactive Lymphocytes Promotes Intratumoral T-cell Persistence and Rejection of Established Tumors. Cancer Res. 2016;76:2087-93. doi:10.1158/0008-5472.CAN-15-3352. PMID:27197251
   PubMed Web of Science ®Google Scholar
• Rupp LJ, Schumann K, Roybal KT, Gate RE, Ye CJ, Lim WA, Marson A. CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells. Sci Rep. 2017;7:737. doi:10.1038/s41598-017-00462-8. PMID:28389661
   PubMed Web of Science ®Google Scholar